Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505088.v1

2023-01-01

Abstract:Figure S3 shows the efficacy of anti-MET VHH pool on tumor growth in individual mouse.

What problem does this paper attempt to address?

Figure S4 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505085

2023-01-01

Abstract:Figure S4 shows the long-term role of anti-MET VHH pool in treating mice.
Figure S2 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505091

2023-01-01

Abstract:Figure S2 shows the specificity of anti-MET VHH pool on MET in killing cancer cells.
Figure S7 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505076

2023-01-01

Abstract:Figure S7 shows the model of anti-MET VHH pool overcoming MET-targeted cancer therapeutic resistance.
A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts

yanlan yu,yicheng chen,guoqing ding,mingchao wang,haiyang wu,liwei xu,xuefang rui,zhigen zhang

DOI: https://doi.org/10.1016/j.bbrc.2015.06.107

IF: 3.1

2015-01-01

Biochemical and Biophysical Research Communications

Abstract:The hepatocyte growth factor and its receptor c-Met are correlated with castration-resistance in prostate cancer. Although HGF has been considered as an attractive target for therapeutic antibodies, the lack of cross-reactivity of monoclonal antibodies with human/mouse HGFs is a major obstacle in preclinical developments. We generated a panel of anti-HGF RabMAbs either blocking HGF/c-Met interaction or inhibiting c-Met phosphorylation. We selected one RabMAb with mouse cross-reactivity and demonstrated that it blocked HGF-stimulated downstream activation in PC-3 and DU145 cells. Anti-HGF RabMAb inhibited not only the growth of PC-3 cells but also HGF-dependent proliferation in HUVECs. We further demonstrated the efficacy and potency of the anti-HGF RabMAb in tumor xenograft mice models. Through these in vitro and in vivo experiments, we explored a novel therapeutic antibody for advanced prostate cancer.
Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Hang-Ping Yao,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1016/j.drudis.2020.11.002

IF: 8.369

2021-01-01

Drug Discovery Today

Abstract:•Cancerous MET overexpression is a common pathological feature manifested by genetic, molecular, and cellular abnormalities.•Conventional therapeutic antibodies targeting MET, under clinical trials for almost 10 years, have made little progress with various setbacks.•Novel biotherapeutics, such as bispecific antibodies, antibody-drug conjugates, and their combination, are under anti-MET clinical trials.•Amivantamab, a MET/EGFR bispecific antibody, has been granted the Breakthrough Therapy Designation status for treatment of advanced NSCLC.•An emerging era of antibody-based biotherapeutics for treatment of cancer overexpressing MET is in the horizon.
Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Xiangheng Chen,Zhonghai Guan,Jun Lu,Haohao Wang,Zhongkun Zuo,Fei Ye,Jiangsheng Huang,Lisong Teng

DOI: https://doi.org/10.7150/jca.20964

IF: 3.9

2018-01-01

Journal of Cancer

Abstract:cMet signaling pathway is involved in the resistance to anti-VEGF therapy and cMet overexpression is associated with tumor progression and poor prognosis. In this study, the expression of cMet in 146 Chinese colorectal cancer (CRC) patients was examined by immunohistochemistry staining. Our data demonstrated that cMet overexpression rate was 42.5% (62/146) and cMet overexpression was closely correlated with distant metastasis of CRC. Using CRC patient-derived xenograft (PDX) mouse models we investigated antitumor activity of a novel selective cMet inhibitor volitinib alone or in combination with anti-VEGF inhibitor apatinib in vivo. Our results showed that combination treatment significantly inhibited tumor growth in two PDX models. While volitinib treatment alone induced moderate improvement in tumor growth inhibition, combination treatment synergistically reduced microvessel density, suppressed proliferation, and increased apoptosis in PDX models. Further analysis showed synergistic inhibition of MAPK and PI3K/Akt pathways by volitinib and apatinib. Taken together, our data provide a rationale to targeting both cMet and VEGF in the treatment of cMet overexpressing CRC in clinical trials.
Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Hang-Ping Yao,Rachel Hudson,Ming-Hai Wang

DOI: https://doi.org/10.1016/j.bbcan.2020.188425

2020-01-01

Abstract:Advanced epithelial cancers such as gastric, lung, and pancreatic tumors are featured by invasive proliferation, distant metastasis, acquired chemoresistance, and tumorigenic stemness. For the last decade, molecular-targeted therapies using therapeutic antibodies, small molecule kinase inhibitors and immune-checkpoint blockades have been applied for these diseases with significant clinical benefits. Nevertheless, there is still a large gap to achieve curative outcomes. MET (mesenchymal-epithelial transition protein), a receptor tyrosine kinase, is a tumorigenic determinant that regulates epithelial cancer initiation, progression, and malignancy. Increased MET expression also has prognostic value for cancer progression and patient survival. These features provide the rationale to target MET for cancer treatment. In this review, we discuss the importance of MET in epithelial tumorigenesis and the development of antibody-based biotherapeutics, including bispecific antibodies and antibody-drug conjugates, for clinical application. The findings from both preclinical and clinical studies highlight the potential of MET-targeted biotherapeutics for cancer therapy in the future.
Abstract LB-015: Differential Therapeutic Responses of MET Oncogenic Activations to Met Kinase Inhibitor and Neutralizing Antibody

Jianqun Kou,Ben Staal,Phillip R. Musich,Liang Kang,Yuan Qin,Zhi Q. Yao,Boheng Zhang,Tam Angela,Alan Huang,Huaixiang Hao,George F. Vande Woude,Qian Xie

DOI: https://doi.org/10.1158/1538-7445.am2018-lb-015

IF: 11.2

2018-01-01

Cancer Research

Abstract:Abstract Purpose: MET inhibitors are in clinical trials against several cancer types, but the mechanisms toward vulnerability remain elusive. Here we characterized the molecular basis of MET amplification (METamp) and HGF-autocrine driven tumors in response to MET tyrosine kinase inhibitors (TKI) and neutralizing antibodies. Experimental Design: METamp (MKN45 and MHCC97H) and HGF-autocrine activation (JHH5 and U87) cells were treated by the MET kinase inhibitor (INC280) and the anti-MET monoclonal antibody (MetMab) to determine the sensitivity and biological responses in vitro. Tumor inhibition was evaluated in vivo using SCID and SCIDhgf mouse models, respectively. HGF-mediated angiogenesis was measured by using the human endothelial cells (HUVEC) tube formation assay. Results: MKN45 and MHCC97H cells are more sensitive than JHH5 and U87 cells to INC280 treatment but are unresponsive to MetMab. In METamp cells, INC280 induced a DNA damage response with activation of repair through the p53BP1/ATM signaling pathway. Although INC280 and MetMab showed a moderate inhibitory effect on - JHH5 and U87 cells in vitro, both treatments potently suppressed tumor growth in mouse models. We found that HGF stimulation promotes human HUVEC cell tube formation via the Src pathway. INC280 or MetMab inhibited tube formation; thus in HGF-autocrine tumors, the endothelial cells are the secondary targets of tumor-derived HGF and MET inhibition. Conclusion: METamp and HGF-autocrine activation favor different molecular mechanisms, such as a DNA damage response or angiogenesis. Because individual types of MET oncogenic activation may respond to MET inhibitors differently, combination strategies should be developed based upon the molecular subtypes of the tumors. Citation Format: Jianqun Kou, Ben Staal, Phillip R. Musich, Liang Kang, Yuan Qin, Zhi Q. Yao, Boheng Zhang, Tam Angela, Alan Huang, Huaixiang Hao, George F. Vande Woude, Qian Xie. Differential therapeutic responses of MET oncogenic activations to Met kinase inhibitor and neutralizing antibody [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-015.
Supplementary Figure S1 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Zheng Zhang,Yang Zhang,Qian Sun,Fei Feng,Muren Huhe,Li Mi,Zhinan Chen

DOI: https://doi.org/10.1158/1535-7163.22501722

2023-01-01

Abstract:Supplementary Figure S1. Images of anti-tumor efficacy of Metuzumab in SCID mice bearing A549 (left) and NCI-H520 (right) human lung cancer cell line xenografts.
Differential Responses of MET Activations to MET Kinase Inhibitor and Neutralizing Antibody.

Jianqun Kou,Phillip R. Musich,Ben Staal,Liang Kang,Yuan Qin,Zhi Q. Yao,Boheng Zhang,Weizhong Wu,Angela Tam,Alan Huang,Huai-Xiang Hao,George F. Vande Woude,Qian Xie

DOI: https://doi.org/10.1186/s12967-018-1628-y

IF: 8.44

2018-01-01

Journal of Translational Medicine

Abstract:BACKGROUND:Aberrant MET tyrosine kinase signaling is known to cause cancer initiation and progression. While MET inhibitors are in clinical trials against several cancer types, the clinical efficacies are controversial and the molecular mechanisms toward sensitivity remain elusive.METHODS:With the goal to investigate the molecular basis of MET amplification (METamp) and hepatocyte growth factor (HGF) autocrine-driven tumors in response to MET tyrosine kinase inhibitors (TKI) and neutralizing antibodies, we compared cancer cells harboring METamp (MKN45 and MHCCH97H) or HGF-autocrine (JHH5 and U87) for their sensitivity and downstream biological responses to a MET-TKI (INC280) and an anti-MET monoclonal antibody (MetMab) in vitro, and for tumor inhibition in vivo.RESULTS:We find that cancer cells driven by METamp are more sensitive to INC280 than are those driven by HGF-autocrine activation. In METamp cells, INC280 induced a DNA damage response with activation of repair through the p53BP1/ATM signaling pathway. Although MetMab failed to inhibit METamp cell proliferation and tumor growth, both INC280 and MetMab reduced HGF-autocrine tumor growth. In addition, we also show that HGF stimulation promoted human HUVEC cell tube formation via the Src pathway, which was inhibited by either INC280 or MetMab. These observations suggest that in HGF-autocrine tumors, the endothelial cells are the secondary targets MET inhibitors.CONCLUSIONS:Our results demonstrate that METamp and HGF-autocrine activation favor different molecular mechanisms. While combining MET TKIs and ATM inhibitors may enhance the efficacy for treating tumors harboring METamp, a combined inhibition of MET and angiogenesis pathways may improve the therapeutic efficacy against HGF-autocrine tumors.
Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases.

Liang Feng,Wei Wang,Hang-Ping Yao,Jianwei Zhou,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1007/978-1-4939-1789-1_14

2015-01-01

Abstract:Targeting receptor tyrosine kinases by therapeutic monoclonal antibodies and antibody-drug conjugates has met with tremendous success in clinical oncology. Currently, numerous therapeutic monoclonal antibodies are under preclinical development. The potential for moving candidate antibodies into clinical trials relies heavily on therapeutic efficacy validated by human tumor xenografts in mice. Here we describe methods used to determine therapeutic efficacy of monoclonal antibodies or antibody-drug conjugates specific to human receptor tyrosine kinase using human tumor xenografts in mice as the model. The end point of the study is to determine whether treatment of tumor-bearing mice with a monoclonal antibody or antibody-drug conjugates results in significant delay of tumor growth.
Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase

Rachel Hudson,Hang-Ping Yao,Sreedhar Reddy Suthe,Dhavalkumar Patel,Ming-Hai Wang

DOI: https://doi.org/10.2174/1568009621666211222154129

2022-01-01

Current Cancer Drug Targets

Abstract:Background: Aberrant expression of the MET receptor tyrosine kinase is an oncogenic determinant and a drug target for cancer therapy. Currently, antibody-based biotherapeutics targeting MET are under clinical trials. Objective: Here, we report the preclinical and therapeutic evaluation of a novel anti-MET antibody-drug conjugate PCMC1D3-duocarmycin SA (PCMC1D3-DCM) for targeted cancer therapy. Methods: The monoclonal antibody PCMC1D3 (IgG1a/kappa), generated by a hybridoma technique and specific to one of the MET extracellular domains, was selected based on its high specificity to human MET with a binding affinity of 1.60 nM. PCMC1D3 was conjugated to DCM via a cleavable valine-citrulline dipeptide linker to form an antibody-drug conjugate with a drug-to-antibody ratio of 3.6:1. PCMC1D3-DCM in vitro rapidly induced MET internalization with an internalization efficacy ranging from 6.5 to 17.2h dependent on individual cell lines. Results: Studies using different types of cancer cell lines showed that PCMC1D3-DCM disrupted the cell cycle, reduced cell viability, and caused massive cell death within 96h after treatment initiation. The calculated IC50 values for cell viability reduction were 1.5 to 15.3 nM. Results from mouse xenograft tumor models demonstrated that PCMC1D3-DCM in a single dose injection at 10 mg/kg body weight effectively delayed xenograft tumor growth up to two weeks without signs of tumor regrowth. The calculated tumoristatic concentration, a minimal dose required to balance tumor growth and inhibition, was around 2 mg/kg body weight. Taken together, PCMC1D3-DCM was effective in targeting the inhibition of tumor growth in xenograft models. Conclusion: This work provides the basis for the development of humanized PCMC1D3-DCM for MET-targeted cancer therapy in the future.
Supplemental Figure 4 Dose-dependent Inhibition from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Anna Li,Jing Yang,Xuchao Zhang,Zhou Zhang,Jian Su,Lan-ying Gou,Y. Bai,Qing Zhou,Zhenfan Yang,Han,Wen‐Zhao Zhong,Shannon Chuai,Qi Zhang,Zhi Xie,Hongfei Gao,Huajun Chen,Zhen Wang,Zheng Wang,Xue‐Ning Yang,Bin-Chao Wang,Bin Gan,Zhihong Chen,Ben‐Yuan Jiang,Si-Pei Wu,Siyang Liu,Chong‐Rui Xu,Yi‐Long Wu

DOI: https://doi.org/10.1158/1078-0432.22463061.v1

2023-01-01

Abstract:A-B. Female nu/nu athymic nude mice bearing MET mY1228H (A) and MET mY1226N (B) were treated with increasing dose of XL184 at 0mg/kg/d, 5mg/kg/d, 20mg/kg/d or 60mg/kg/d. Dose-dependent inhibition was observed for both mutations (Non-linear mixed effect model, p<0.0001).
Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Lu Xu,Eiki Kikuchi,Chunxiao Xu,Hiromichi Ebi,Dalia Ercan,Katherine A. Cheng,Robert Padera,Jeffrey A. Engelman,Pasi A. Jänne,Geoffrey I. Shapiro,Takeshi Shimamura,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22391819.v1

2023-01-01

Abstract:PDF file - 1.4MB, Supplemental Figure 1. MET is inducible in MET, TD/MET, and TL/MET models Supplemental Figure 2. Quantification of hMET expression in mouse models Supplemental Figure 3. Comparison of the tumor counts in mutant EGFR lung tumors with or without expression of hMET. Supplemental Figure 4. Representative MRI images prior to and after treatment in TL and TL/MET mice. Supplemental Figure 5. Xenografts of HCC827GR6 cells ectopically expressing EGFR E746_A750del/T790M are sensitive to the combination of WZ4002 and 17-DMAG. Supplemental Figure 6. The WZ4002/crizotinib or WZ4002/17-DMAG combinations suppress phosphorylation of EGFR, Akt, and Erk in TD and TD/MET to a greater extent than individual treatments
Supplementary Figure 3 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Hongkui Jin,Renhui Yang,Zhong Zheng,Mally Romero,Jed Ross,Hani Bou-Reslan,Richard A.D. Carano,Ian Kasman,Elaine Mai,Judy Young,Jiping Zha,Zemin Zhang,Sarajane Ross,Ralph Schwall,Gail Colbern,Mark Merchant

DOI: https://doi.org/10.1158/0008-5472.22373640.v1

2023-01-01

Abstract:Supplementary Figure 3 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
Supplementary Data from A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models

John O. DaSilva,Katie Yang,Andrés E. Perez Bay,Julian Andreev,Peter Ngoi,Erica Pyles,Matthew C. Franklin,Drew Dudgeon,Ashique Rafique,Anthony J. Dore,Frank J. Delfino,Terra Potocky,Robert G. Babb,Gang Chen,Douglas MacDonald,William C. Olson,Gavin Thurston,Christopher Daly

DOI: https://doi.org/10.1158/1078-0432.22479116

2023-01-01

Abstract:Supplementary figure legends and methods
Supplementary Figure S1 from MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING

Yong Zhang,Qifan Yang,Xiangyu Zeng,Manxiang Wang,Shuang Dong,Bin Yang,Xinyi Tu,Ting Wei,Wenzhuan Xie,Chao Zhang,Qiang Guo,Jake A. Kloeber,Yunxia Cao,Guijie Guo,Qin Zhou,Fang Zhao,Jinzhou Huang,Li Liu,Kai Zhang,Mingwei Wang,Ping Yin,Kuntian Luo,Min Deng,Wootae Kim,Jing Hou,Shuang Yu,Qian Zhu,Lifeng Chen,Sheng Hu,Junqiu Yue,Guoliang Pi,Zhenkun Lou

DOI: https://doi.org/10.1158/2159-8290.22540859.v1

2023-01-01

Abstract:Case report of resistance to ICB in patients with MET amplification and MET is a biomarker and driver for ICB resistance
Supplementary Figure 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Hongkui Jin,Renhui Yang,Zhong Zheng,Mally Romero,Jed Ross,Hani Bou-Reslan,Richard A.D. Carano,Ian Kasman,Elaine Mai,Judy Young,Jiping Zha,Zemin Zhang,Sarajane Ross,Ralph Schwall,Gail Colbern,Mark Merchant

DOI: https://doi.org/10.1158/0008-5472.22373646.v1

2023-01-01

Abstract:Supplementary Figure 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
Supplemental Figure 3 Functional Validations of MET Y1248H and D1246N from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Anna Li,Jing Yang,Xuchao Zhang,Zhou Zhang,Jian Su,Lan-ying Gou,Y. Bai,Qing Zhou,Zhenfan Yang,Han,Wen‐Zhao Zhong,Shannon Chuai,Qi Zhang,Zhi Xie,Hongfei Gao,Huajun Chen,Zhen Wang,Zheng Wang,Xue‐Ning Yang,Bin-Chao Wang,Bin Gan,Zhihong Chen,Ben‐Yuan Jiang,Siyuan Wu,Siyang Liu,Chong‐Rui Xu,Yi‐Long Wu

DOI: https://doi.org/10.1158/1078-0432.22463064.v1

2023-01-01

Abstract:A and C. NIH3T3 cells harboring either mouse MET Y1228H or mouse MET D1226N were treated with savolitinib (A) or BMS777607 (C) at indicated concentrations. Viable cells were measured after 72 hours of treatment. Error bars represent standard deviation of biological triplicates. B and D. After treatment with savolitinib (B) and bms777607 (D), cell extracts were immunoblotted to detect total protein levels and phosphorylated forms of key downstream effectors of MET and major cross-talk pathway participants. GAPDH is used as a loading control.
Supplementary Figure 2 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Hongkui Jin,Renhui Yang,Zhong Zheng,Mally Romero,Jed Ross,Hani Bou-Reslan,Richard A.D. Carano,Ian Kasman,Elaine Mai,Judy Young,Jiping Zha,Zemin Zhang,Sarajane Ross,Ralph Schwall,Gail Colbern,Mark Merchant

DOI: https://doi.org/10.1158/0008-5472.22373643

2023-01-01

Abstract:Supplementary Figure 2 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S4 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S2 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S7 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts

Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Abstract LB-015: Differential Therapeutic Responses of MET Oncogenic Activations to Met Kinase Inhibitor and Neutralizing Antibody

Supplementary Figure S1 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Differential Responses of MET Activations to MET Kinase Inhibitor and Neutralizing Antibody.

Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases.

Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase

Supplemental Figure 4 Dose-dependent Inhibition from Acquired &lt;i&gt;met&lt;/i&gt; Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Figure 3 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Supplementary Data from A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models

Supplementary Figure S1 from MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING

Supplementary Figure 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Supplemental Figure 3 Functional Validations of MET Y1248H and D1246N from Acquired &lt;i&gt;met&lt;/i&gt; Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Supplementary Figure 2 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Supplemental Figure 4 Dose-dependent Inhibition from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Supplemental Figure 3 Functional Validations of MET Y1248H and D1246N from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer